No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
DGX Quest Diagnostics
- 136.640
- -0.450-0.33%
Close Jul 2 16:00 ET
- 137.620
- +0.980+0.72%
Post 19:59 ET
15.18BMarket Cap18.39P/E (TTM)
138.050High136.350Low1.05MVolume137.060Open137.090Pre Close143.65MTurnover0.95%Turnover Ratio18.24P/E (Static)111.09MShares145.62052wk High2.36P/B15.05BFloat Cap117.59652wk Low3.59Dividend TTM110.18MShs Float164.773Historical High2.63%Div YieldTTM1.24%Amplitude2.610Historical Low136.998Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
How Is The Market Feeling About Quest Diagnostics?
Quest Diagnostics's (NYSE:DGX) short percent of float has fallen 10.99% since its last report. The company recently reported that it has 2.36 million shares sold short, which is 2.43% of all regular s
Quest Diagnostics Releases 2023 Corporate Responsibility Report
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today released its 2023 Corporate Responsibility Report. This year's...
Express News | Quest Diagnostics Inc: Financial Details Were Not Disclosed
Express News | Quest Diagnostics and Allina Health Announce Agreement for Quest to Acquire Select Laboratory Assets, Aiming to Improve Access and Affordability of Services in Minnesota and Western Wisconsin; No Terms Disclosed
Express News | Quest Diagnostics Inc - Transaction Expected to Complete in Q3 2024
Express News | Quest Diagnostics Inc - to Offer Lab Services to Allina Health Clinic Physicians
Comments
$Quest Diagnostics(DGX.US$ PathAI + Invigorate + stable finance + qualified management team + decent PE.
Will it dominate pathology and cancer diagnosis with AI in the future? Worth noting.
Will it dominate pathology and cancer diagnosis with AI in the future? Worth noting.
4
Quest Diagnostics' consistent ROCE and increased capital employed over the past five years suggest steady reinvestment at good returns. This trend, reflected in the stock's strong performance, is expected to continue.
The acquisition aligns with Quest's strategy to grow through accretive outreach laboratory acquisitions and expands its ability to serve providers and patients in Ohio and Pennsylvania.
The CEO of Quest Diagnostics, Jim Davis, believes Yuri Fesko's deep medical expertise and patient-care advocacy will greatly contribute to the company's strategic decisions. His appointment especially bolsters Quest's efforts to improve customer experiences via diagnostic innovations.
Quest Diagnostics shows favorable metrics with robust reinvestment strategies. Significant earnings growth and an anticipated rise in future ROE, despite a higher payout ratio, hint at other growth factors.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
